Table 3.
Other Treatments of Interest Dispensed at Least Once in Patients Treated by Bx/TSD for a T2 Disease
| Disease [ATC Classification] (%) | AD n=3981 | CRSwNP n=333 | SA n=12,889 | CSU N=2681 |
|---|---|---|---|---|
| Psychoactive drugs* | ||||
| Antihistaminic [R06A] | 48.0 | 55.6 | 61.7 | 74.9 |
| Anxiolytics [N05B] | 7.0 | 7.2 | 11.1 | 23.3 |
| Hypnotics and sedatives [N05C] | 20.6 | 14.7 | 23.3 | 28.5 |
| Vaccines* | ||||
| Influenza vaccine [J07BB] | 17.6 | 28.8 | 47.8 | 25.4 |
| Pneumococcal vaccine [J07AL] | 4.4 | 2.1 | 4.9 | 2.2 |
| Antibiotics* | ||||
| Penicillins with extended spectrum [J01CA] | 21.2 | 34.8 | 35.6 | 22.3 |
| Macrolides, lincosamides and streptogramins [J01F] | 7.8 | 12.9 | 22.7 | 10.0 |
| Others antibacterials [J01X] | 5.2 | 11.7 | 9.8 | 4.0 |
| Others beta-lactam antibacterials (ie, cephalosporins) [J01D] | 3.2 | 12.9 | 8.9 | 4.0 |
| Quinolone antibacterials [J01M] | 3.1 | 10.5 | 8.1 | 4.0 |
Note: *At least 1 delivery during the study period from April 2021 to March 2022.
Abbreviations: AD, atopic dermatitis; ATC, anatomical therapeutic chemical; Bx/TSD, biologic/targeted synthetic treatments; CRSwNP, nasal polyposis; SA, severe asthma; U, urticaria.